Lassa Fever Clinical Course and Prognostic Factors in Nigeria

Summary

The investigators propose to conduct a nationwide (Nigeria), prospective, non-interventional cohort study describing the clinical course, biological characteristics, case management and outcomes in patients hospitalized for a suspected or confirmed diagnosis of Lassa fever in tertiary medical facilities situated in the most affected Nigerian states. Special focuses will be made on situations at risk of bad outcome such as pregnancies, acute kidney injury and electrolytic imbalance in patients with confirmed Lassa fever. Participants for which the diagnosis of Lassa fever will be finally excluded by reverse-transcriptase polymerase chain reaction (RT-PCR) will constitute the control group.

Conditions

• Lassa Fever
• Lassa Virus Infection
• Pregnancy Complications
• Acute Kidney Injury
• Acute Kidney Failure
• Coma

Interventions

OTHER

Non interventional research

Participants are receiving the standard of care according to Nigerian Center for Disease Control (NCDC) Standard Operating Procedures for Lassa fever case management. This include the administration of intravenous ribavirin for Lassa confirmed cases as well as critically-ill Lassa suspected cases.

Sponsors & Collaborators

• Institut National de la Santé Et de la Recherche Médicale, France

  collaborator OTHER_GOV

• University of Oxford

  collaborator OTHER

• Irrua Specialist Teaching Hospital

  collaborator OTHER

• Bernhard Nocht Institute for Tropical Medicine

  collaborator OTHER_GOV

• University Hospital, Bordeaux

  collaborator OTHER

• University of Bordeaux

  collaborator OTHER

• PACCI Program

  collaborator OTHER

• Institut de Recherche pour le Developpement

  collaborator OTHER_GOV

• ANRS, Emerging Infectious Diseases

  collaborator OTHER_GOV

• Federal Medical Centre, Owo

  collaborator INDUSTRY

• European and Developing Countries Clinical Trials Partnership (EDCTP)

  collaborator OTHER_GOV

• Alliance for International Medical Action

  lead OTHER

Principal Investigators

• Denis Malvy, MD, PhD · Inserm 1219 - Infectious Diseases in Ressource Limited Countries

• Oladele O Ayodeji, MD · Owo Federal Medical Centre

Eligibility

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-04-05

Primary Completion

2023-04-30

Completion

2025-12-31

Countries

• Nigeria

Study Locations